Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Net Cash Flow (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Net Cash Flow for 9 consecutive years, with $14.7 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 143.33% to $14.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.2 million through Dec 2025, up 134.87% year-over-year, with the annual reading at $31.2 million for FY2025, 134.87% up from the prior year.
  • Net Cash Flow hit $14.7 million in Q4 2025 for Protagonist Therapeutics, up from -$54.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $183.1 million in Q2 2024 to a low of -$224.5 million in Q3 2024.
  • Historically, Net Cash Flow has averaged $553750.0 across 5 years, with a median of -$1.5 million in 2023.
  • Biggest five-year swings in Net Cash Flow: plummeted 4524.55% in 2024 and later soared 399.48% in 2025.
  • Year by year, Net Cash Flow stood at $3.1 million in 2021, then crashed by 975.43% to -$27.1 million in 2022, then plummeted by 61.34% to -$43.8 million in 2023, then increased by 22.67% to -$33.9 million in 2024, then soared by 143.33% to $14.7 million in 2025.
  • Business Quant data shows Net Cash Flow for PTGX at $14.7 million in Q4 2025, -$54.8 million in Q3 2025, and $29.0 million in Q2 2025.